What Is Vaginal Atrophy — And Why No One Warned You About It

There's a specific experience I hear described again and again in consultations. A woman notices something has changed — sex has become uncomfortable, or she's getting UTIs that never used to happen, or something just feels different in a way she can't quite name. She mentions it to her doctor. She's told it's part of getting older. She's handed a sample of lubricant. She goes home and starts wondering if this is just what the rest of her life feels like.

That consultation gap — between what's happening to her body and what she's been told — is exactly why I'm writing this.

Vaginal atrophy is one of the most common conditions affecting postmenopausal women, one of the most treatable, and one of the most consistently undertreated. Part of the reason is the name, which women don't use in conversation and doctors don't explain. Part of the reason is that it takes years to become severe enough that a woman actively seeks help. And part of the reason is a genuine gap in how menopause is taught and discussed in American medicine.

The Name Nobody Uses

The clinical term is genitourinary syndrome of menopause, or GSM. It replaced the older term "vaginal atrophy" a few years ago because doctors realized the condition affects more than just the vaginal canal — it involves the vulva, urethra, and bladder as well. But "vaginal atrophy" is still used widely, and "atrophy" is the right word for what's happening: tissue that was once thick, elastic, and well-supplied with blood is losing those properties.

Most women don't know any of this. They know something feels wrong. They describe it as dryness, or sensitivity, or pain they didn't have before. They're not wrong — those are real symptoms. But they're symptoms of an underlying tissue change, not a surface problem. And that distinction matters enormously for how you treat it.

What Actually Happens to the Tissue

Before menopause, estrogen keeps the vaginal lining thick, flexible, and consistently lubricated. A healthy premenopausal vaginal wall has anywhere from 20 to 30 cell layers. It maintains an acidic pH that protects against infection. It has good blood supply, which supports natural lubrication and keeps the tissue resilient.

When estrogen production drops after menopause, those cell layers start to reduce. Over the first few years, the lining can thin to as few as 3 to 5 cell layers. The blood supply decreases. The pH rises toward alkaline, which makes it easier for bacteria to establish themselves — explaining the recurring UTIs and infections so many postmenopausal women experience. Collagen in the tissue breaks down. Elasticity is lost. The vaginal wall gradually shortens and narrows.

None of this is visible from the outside. A woman can feel completely normal in her daily life and still have significant atrophy developing internally. That's part of why so many women go years without connecting the dots between what they feel and what's happening at a cellular level.

The Symptoms Women Describe (And What They Mean)

Dryness that doesn't respond to lubricants. Lubricants work by adding surface moisture — they address a symptom, not the cause. When the tissue itself has thinned and lost its natural secretory function, a lubricant adds moisture the same way a coat of paint adds color to crumbling plaster. It looks better temporarily. It doesn't fix what's underneath.

Pain or discomfort during sex. This isn't psychological, and it isn't inevitable. It's a mechanical consequence of tissue that's thinner, less elastic, and less lubricated than it needs to be. It often becomes progressively worse over time if the underlying atrophy isn't addressed.

Recurring UTIs. When the vaginal pH rises and the protective tissue barrier thins, bacteria that couldn't previously colonize the area can establish themselves more easily. Many women don't make this connection — they've been treating the infections individually without anyone identifying the underlying change that's making them more frequent.

Urinary urgency or leakage. The same estrogen withdrawal that affects the vaginal tissue also affects the urethra and bladder. Some women experience increased urgency or find they're less able to hold urine. This too is usually treated as an isolated problem rather than as one manifestation of a single underlying shift.

Why Lubricants Don't Solve It

Lubricants serve a real purpose. For women with mild symptoms, or as a short-term comfort measure, they help. But they are not a treatment for vaginal atrophy, and the fact that they're frequently offered as one is part of why so many women feel like nothing works.

The core problem is that lubricants are topical moisturizers applied to a surface. Vaginal atrophy is a structural change happening inside the tissue itself. The cell layers aren't thinning from the outside in — they're thinning because of the absence of estrogen signaling at the cellular level. A lubricant can't reach that process. It can make the surface feel temporarily better, but within a few hours, the underlying tissue is still the same.

Long-term moisturizers do slightly better — they maintain surface hydration over a longer period — but they still don't address the structural change. They are management, not treatment. And for women whose atrophy is progressive, management strategies eventually become insufficient.

Why So Many Women Go Untreated for Years

There are several reasons, and they compound each other. The first is that early-stage atrophy is uncomfortable but manageable. Women adapt — they change how they move, avoid activities that cause discomfort, quietly stop having sex. The symptoms don't arrive as a named package; they arrive as individual inconveniences spread over months or years.

The second reason is that most primary care physicians in the United States receive minimal menopause training. Medical school curricula give vaginal atrophy and GSM very little time. Doctors are often not thinking about it, not screening for it, and not familiar with the full range of treatment options — including the topical estrogen therapies that have been standard care in Europe for decades.

The third reason is the 2002 Women's Health Initiative study, which concluded that hormone replacement therapy increased breast cancer risk. That finding — applied to oral, systemic, combined HRT — scared an entire generation of physicians away from anything with "estrogen" in the name. But topical vaginal estriol is not oral systemic HRT. It's a different route, a different molecule, and a different risk profile. The fear transferred. And women are still falling through that gap today.

The Treatment That Changes the Equation

The reason this condition is fully reversible is that the tissue hasn't died — it's been deprived of the signal that maintains it. When you restore that signal, the tissue responds. Cell layers begin to regrow. Blood supply improves. pH normalizes. Elasticity returns. Women who have had atrophy for years describe the change as feeling like their body remembers what it was supposed to do.

The treatment is topical estriol — one of three estrogens the body naturally produces, applied directly to vaginal tissue where it's absorbed locally. Because it's applied topically rather than taken orally, it doesn't flood the bloodstream. It goes where it's needed and signals the tissue to rebuild.

In Europe, this isn't a controversial treatment. It has been standard care since the 1970s. The UK's medicines regulator reviewed all the evidence in 2022 and decided that topical vaginal estriol is so safe it's available over the counter — no prescription required. Finland and Denmark made the same call. For American women, the access pathway is different, but the treatment is the same, backed by 50 years of European clinical practice.

Dr. Umair Khalid, MBBS